Cipher Pharmaceuticals Inc.
TSX:CPH.TODrug Manufacturers - Specialty & Generic
+$0.15 today
- Market cap
- $331.67M
- Beta
- 0.48
- P/E (TTM)
- 9.3
- EPS (TTM)
- $1.22
Volume 0.04M
Average 0.03M
CPH.TO Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Cipher Pharmaceuticals Inc.TSX: CPH.TO
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin narrows to 67.9%
Gross margin was 67.9% in Q1 FY2026, down 8.2 pp from a year earlier. On a trailing-twelve-month basis it was 74.5%, up 2.6 pp year over year. Over 3 fiscal years it narrowed by 14.9 pp.
Context
- Gross margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 65.8%
- Year-over-year change
- -6.5pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 65.8% | -6.5pp |
| FY2024 | 2024-12-31 | 72.2% | -8.5pp |
| FY2023 | 2023-12-31 | 80.8% | +0.1pp |
| FY2022 | 2022-12-31 | 80.7% | -2.5pp |
| FY2021 | 2021-12-31 | 83.2% | — |
Gross Margin vs competitors
How CPH.TO compares with its peers on the latest reported figures
- CPH.TO's LTM Mar 2026 gross margin of 74.5% is the 2nd highest of the 8 companies compared; the peer median is 31.5%.
- Its year-over-year change of +2.6 pp is the highest of 8, against a peer median of -7.6 pp.
- Over three fiscal years its change of -14.9 pp compares with a peer median of -1.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 92.2% | +1.9 pp | -2.8 pp | |
| LTM Mar 2026 | 74.5% | +2.6 pp | -14.9 pp | |
| LTM Mar 2026 | 50.9% | -0.7 pp | +0.4 pp | |
| LTM Mar 2026 | 37.3% | -7.6 pp | -13.5 pp | |
| LTM Mar 2026 | 31.5% | -23.2 pp | +32.8 pp | |
| LTM Mar 2026 | 23.6% | -5.9 pp | +54.0 pp | |
| LTM Mar 2026 | -3.1% | -35.8 pp | — | |
| LTM Mar 2026 | -79.2% | -128.4 pp | -270.1 pp | |
| Peer median (excluding CPH.TO) | 31.5% | -7.6 pp | -1.2 pp | |
Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.94M | 20.68M | 21.16M | 33.36M | 51.33M |
| Cost of Revenue | 3.68M | 3.99M | 4.07M | 9.26M | 17.56M |
| Gross Profit | 18.26M | 16.68M | 17.09M | 24.1M | 33.77M |
| Gross Margin | 83.2% | 80.7% | 80.8% | 72.2% | 65.8% |
| Research & Development | 88K | 98K | 139K | 0 | 21.37K |
| Selling, General & Admin | 5.11M | 4.4M | 5.43M | 12.24M | 16.3M |
| Operating Expenses | 6.45M | 5.63M | 5.56M | 16.26M | 16.97M |
| Depreciation & Amortization | 701K | 989K | 1.23M | 4.02M | 7.23M |
| EBITDA | 13.66M | 12.04M | 11.53M | 11.87M | 24.1M |
| EBITDA Margin | 62.2% | 58.2% | 54.5% | 35.6% | 46.9% |
| Operating Income | 11.82M | 12.04M | 11.53M | 7.85M | 16.8M |
| Operating Margin | 53.9% | 58.2% | 54.5% | 23.5% | 32.7% |
| Interest Income | 12K | 464K | 1.87M | 330K | 0 |
| Interest Expense | 92K | 0 | 0 | 0 | 1.19M |
| Other Income / Expenses | (2M) | (560K) | 1.15M | (4.89M) | 661.38K |
| Income Before Tax | 11.06M | 11.48M | 12.68M | 2.96M | 17.46M |
| Pre-Tax Margin | 50.4% | 55.5% | 59.9% | 8.9% | 34.0% |
| Income Tax Expense | 3.3M | (15.16M) | (7.7M) | (8.59M) | (10.34M) |
| Net Income | 7.76M | 26.64M | 20.38M | 11.55M | 27.81M |
| Net Margin | 35.4% | 128.8% | 96.3% | 34.6% | 54.2% |
| EPS (Basic) | 0.29 | 1.06 | 0.80 | 0.47 | 1.09 |
| EPS (Diluted) | 0.29 | 1.04 | 0.80 | 0.47 | 1.07 |
| Weighted Avg Shares | 26.6M | 25.13M | 25.48M | 24.72M | 25.48M |
| Weighted Avg Shares (Diluted) | 26.83M | 25.59M | 25.42M | 24.57M | 25.99M |
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
Intrinsic Alpha fair value
Locked
Current Price
$13.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.